Devicare Launches its New Urology Treatment in the Netherlands

Devicare, a Spanish company specializing in the field of urology will begin distributing a new product called Canoxidin in the Netherlands, as confirmed by Rosendo Garganta, CEO of Devicare.

It is a new medical treatment to reduce incrustations and prevent the risk of urinary tract infection associated with permanent or temporary urological medical devices. Canoxidin combines the action of an acidifier, L-methionine, with crystallization inhibitors such as phytates and theobromine.

Acidification is necessary to compensate for the alkalinization of urine pH associated with the installation of permanent or semi-permanent urological devices. Maintaining urine pH in an acidic range promotes the generation of nitric oxide, a bactericidal molecule. Increasing the concentration of inhibitors in the urine prevents crystallization and deposition of calcium and uric acid crystals on the internal and external surfaces of the urological device.

Read more about Devicare and find the latest business headlines of the day with the Born2Invest mobile app.

Devicare had a turnover of one million euros in the year of the outbreak of the pandemic

This product is the first of its kind on a global scale, Garganta pointed out. It is a tablet that is taken three times a day and is aimed at anyone who can carry a catheter, from the elderly in residential centers to patients with spinal cord damage.

For the time being, Devicare is launching this product in the Netherlands, but expects Canoxidin to be marketed and distributed in Malta and Spain during the course of the year, according to the company’s CEO. In fact, the company will soon have its own team to sell its products, Garganta adds.

Devicare had a turnover of one million euros in 2020. Since its founding, the Spanish urology company has raised more than ten million in financing. The company’s goal for the next few years is also to reach 80 countries.

The Spanish company acquired its Urogelus product from M4 Pharma last year

At the beginning of 2021, the company closed a financing round of $3 million. The deal was led by medical technology company Advanced MedTech, owned by Temasek Holdings, Singapore’s sovereign wealth fund. Advanced MedTech is a medical technology company with a focus on urology.

In February 2021, Devicare acquired its Urogelus product from M4 Pharma with the aim of strengthening its presence in this therapeutic area. M4 Pharma is a laboratory dedicated to the commercialization of pharmaceuticals in ophthalmology, ENT and urology.

Days later, Devicare announced a restructuring of its board of directors, with the incorporation of the first three independent members, in addition to two observers. They are Josep Gatell, CEO of a medical technology business group comprising Cardiolink, Swan Medical, and Ilerimplant; Carlos Moreu, CEO of M4 Pharma; Abel Ang, CEO of Advanced MedTech Holdings; Luís Balbás, managing director of southern Europe at Dornier MedTech; and Maite Fibla, founder of Ship2B Ventures.

Devicare’s board now consists of five directors and two observers. The other members are Rosendo Garganta, Roberto Costillas and Marc Palà, who represent Emesa Corporación Empresarial.

__

(Featured image by 334557 via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.